Moore Paul Andrew reported option exercise involving 25,000 derivative units of Zymeworks Inc. at $0.00 for $0 on Nov 13, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Scientific Officer
Chief Scientific Officer
Filed Nov 16, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
25,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
175,000Direct
Trade date
Nov 13, 2026Option exercise
Filed
Nov 16, 2026, 6:16 AM ET3-day reporting delay
Accession
0001938192-26-000007Code M · Transaction 401650
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

ZYME price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ZYME · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 23, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −16%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.07 to $26.21, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.05 to $26.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.95 to $26.11, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.